At a glance

In Canada, we currently employ approximately 1,628 full time employees across the country, providing a salary injection of $94 million into the Canadian economy. We have two divisional headquarters in Mississauga, Ontario and Montréal, Quebec, and an administrative office in Quebec City.

Locations

100 Milverton Drive
Suite 800
Mississauga, Ontario
L5R 4H1
Canada
Tel: 905-819-3000

75, rue Queen, suite 1400
Montréal, Québec
H3C 2N6
Canada
Tel: 1-833-737-1277

2323, boul. Du Parc technologique
Québec
G1P 4R8
Canada
Tel: 418-650-0010

2324 du parc technologique Blvd.
Ste-Foy, Québec
G1P 4R8
Canada
Tel: 418-650-0010

Manufacturing

The Ste-Foy vaccine manufacturing site currently produces an important share of Canada’s seasonal influenza vaccine and responsible for the domestic supply of the country’s pandemic influenza vaccine requirements.

Research & development

We have invested more than $2 billion since 2001 in Canadian pharmaceutical and vaccines Research & Development (R&D), with over 121 million in 2023 alone. In 2023, we invested over $18.4 million into 53 active clinical trials across Canada involving 3,334 active subjects.

Community investment

We are committed to working in partnership with charities and community based organizations who reflect our key values, supporting programs with a local, national or international reach.

Community partnerships in Canada

$590k

invested in grants and donations to community groups by GSK in Canada in 2024

$3 mil +

contributed over the last 20 years to support the hospice palliative care movement in Canada. In 2024 only, we contributed $100,000 to help ensure every Canadian has access to quality hospice palliative care.

11.5k+

emergency backpacks have been assembled since 2016 by GSK and Save The Children Canada and have been used as part of emergency preparedness and resiliency programming with Indigenous children, families and communities in Alberta, Saskatchewan, Manitoba, Ontario, and Quebec.

Environmental sustainability

In October 2018, we launched a Centralized Waste program involving the removal of individual waste containers from offices to promote environmental consciousness and reduce our contribution to landfills.

In November 2020, as a global biopharmaceutical company we announced ambitious new environmental sustainability goals in both climate and nature, aiming to have a net zero impact on climate and a net positive impact on nature by 2030, across our entire value chain – from lab to patient. We’ve set clear and measurable targets to help achieve these goals.

Our global sustainability goals and targets